Clinical trial · Observational
Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01
Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01 Weekly Erlotinib for Familial Adenomatous Polyposis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This particular part of the study could not be completed as endoscopy reports post completion of erlotinib trial were distributed across community and other hos
Summary
Brief summary (as posted)
This study reviews post study clinical endoscopy reports in follow up to patients who participated in MAY2016-07-01 with weekly erlotinib for familial adenomatous polyposis. Reviewing follow up medical records may help researchers examine the extent of rapid progression of familiar adenomatous polyposis disease burden after discontinuation of weekly erlotinib.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Familial Adenomatous Polyposis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Electronic Health Record Review | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational (medical record review)
- description
- Patients who participated in MAY2016-07-01 undergo review of medical records.
- interventionNames
- Other: Electronic Health Record Review
Primary outcomes (3)
- measure
- Number of study participants exhibiting clinically significant progression of duodenal neoplasia after completion of study drug
- timeFrame
- At completion of study
- description
- Will be assessed by endoscopy.
- measure
- Number of participants who underwent surgical resection
- timeFrame
- At completion of study
- description
- Will determine the number of participants who underwent surgical resection for management of advanced upper gastrointestinal (GI) neoplasia/cancer between the date of completion of intervention and 2/28/2021.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * MAY2016-07-01 study participants for whom medical records are available and accessible Exclusion Criteria: * MAY2016-07-01 study participants who have opted out of medical records reviews or for whom consent for medical record review cannot be confirmed/documented
References
Publications (0)
Data not yet available